Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Primary immunodeficiency is defined as a weakened immune system that results in repeated infections and other health problems occurring more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea, and diarrhea.
The Primary Immune Deficiency drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Immune Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Immune Deficiency and features dormant and discontinued projects.
Key Targets in the Primary Immune Deficiency Pipeline Products Market
The key targets in the Primary Immune Deficiency pipeline products market are Cytokine Receptor Common Subunit Gamma, C-X-C Chemokine Receptor Type 4, Adenosine Deaminase, Protein Artemis, CD40 Ligand, Immunoglobulin G, Interleukin 2 Receptor, Mast/Stem Cell Growth Factor Receptor Kit, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoformy, Serine/Threonine Protein Kinase mTOR, and others.
Primary Immune Deficiency Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Primary Immune Deficiency Pipeline Products Market
The key mechanisms of action in the Primary Immune Deficiency pipeline products market are Cytokine Receptor Common Subunit Gamma Activator, C-X-C Chemokine Receptor Type 4 Antagonist, Adenosine Deaminase Activator, Protein Artemis Activator, CD40 Ligand Activator, Interleukin 2 Receptor Agonist, Mast/Stem Cell Growth Factor Receptor Kit Antagonist, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Serine/Threonine Protein Kinase mTOR Inhibitor, Signal Transducer And Activator Of Transcription 3 Activator, and others.
Primary Immune Deficiency Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Primary Immune Deficiency Pipeline Products Market
The key routes of administration in the Primary Immune Deficiency pipeline products market are intravenous, parenteral, subcutaneous, oral, intramuscular, and topical.
Primary Immune Deficiency Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Primary Immune Deficiency Pipeline Products Market
The key molecule types in the Primary Immune Deficiency pipeline products market are gene-modified cell therapy, antibody, small molecule, cell therapy, biologic, gene therapy, monoclonal antibody, recombinant enzyme, and recombinant protein.
Primary Immune Deficiency Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Primary Immune Deficiency Pipeline Products Market
Some of the major companies in the Primary Immune Deficiency pipeline products market are Takeda Pharmaceutical Co Ltd, X4 Pharmaceuticals Inc, ADMA Biologics Inc, Cellectis SA, Grifols SA, Mustang Bio Inc, Biotest AG, Cellective BioTherapy Inc, Chengdu Rongsheng Pharmaceutical Co Ltd, and Clinigen Group Plc.
Primary Immune Deficiency Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
| Key targets | Cytokine Receptor Common Subunit Gamma, C-X-C Chemokine Receptor Type 4, Adenosine Deaminase, Protein Artemis, CD40 Ligand, Immunoglobulin G, Interleukin 2 Receptor, Mast/Stem Cell Growth Factor Receptor Kit, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoformy, Serine/Threonine Protein Kinase mTOR, and Others |
| Key mechanism of action | Cytokine Receptor Common Subunit Gamma Activator, C-X-C Chemokine Receptor Type 4 Antagonist, Adenosine Deaminase Activator, Protein Artemis Activator, CD40 Ligand Activator, Interleukin 2 Receptor Agonist, Mast/Stem Cell Growth Factor Receptor Kit Antagonist, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Serine/Threonine Protein Kinase mTOR Inhibitor, Signal Transducer And Activator Of Transcription 3 Activator, and Others |
| Key routes of administration | Intravenous, Parenteral, Subcutaneous, Oral, Intramuscular, and Topical |
| Key molecule type | Gene-Modified Cell Therapy, Antibody, Small Molecule, Cell Therapy, Biologic, Gene Therapy, Monoclonal Antibody, Recombinant Enzyme, and Recombinant Protein |
| Major companies | Takeda Pharmaceutical Co Ltd, X4 Pharmaceuticals Inc, ADMA Biologics Inc, Cellectis SA, Grifols SA, Mustang Bio Inc, Biotest AG, Cellective BioTherapy Inc, Chengdu Rongsheng Pharmaceutical Co Ltd, and Clinigen Group Plc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Biotest AG
Cellectis SA
Cellective BioTherapy Inc
Chengdu Rongsheng Pharmaceutical Co Ltd
Clinigen Group Plc
CSL Ltd
EmendoBio Inc
Evolve Biologics Inc
Genespire Srl
Graphite Bio Inc
Grifols SA
Grifols Therapeutics Inc
Jasper Therapeutics Inc
Kedrion SpA
Lactiga Inc
Liminal BioSciences Inc
Microgen
Mustang Bio Inc
Noga Therapeutics Ltd
Novartis AG
Octapharma AG
Orchard Therapeutics Plc
Pfizer Inc
Smart Immune SAS
Sumitomo Dainippon Pharma Co Ltd
Taiga Biotechnologies Inc
Takeda Pharmaceutical Co Ltd
X4 Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Primary Immune Deficiency products market?
The key targets in the Primary Immune Deficiency pipeline products market are Cytokine Receptor Common Subunit Gamma, C-X-C Chemokine Receptor Type 4, Adenosine Deaminase, Protein Artemis, CD40 Ligand, Immunoglobulin G, Interleukin 2 Receptor, Mast/Stem Cell Growth Factor Receptor Kit, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoformy, Serine/Threonine Protein Kinase mTOR, and others.
-
What are the key mechanisms of action in the Primary Immune Deficiency pipeline products market?
The key mechanisms of action in the Primary Immune Deficiency pipeline products market are Cytokine Receptor Common Subunit Gamma Activator, C-X-C Chemokine Receptor Type 4 Antagonist, Adenosine Deaminase Activator, Protein Artemis Activator, CD40 Ligand Activator, Interleukin 2 Receptor Agonist, Mast/Stem Cell Growth Factor Receptor Kit Antagonist, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Serine/Threonine Protein Kinase mTOR Inhibitor, Signal Transducer And Activator Of Transcription 3 Activator, and others.
-
What are the key routes of administration in the Primary Immune Deficiency pipeline products market?
The key routes of administration in the Primary Immune Deficiency pipeline products market are intravenous, parenteral, subcutaneous, oral, intramuscular, and topical.
-
What are the key molecule types in the Primary Immune Deficiency pipeline products market?
The key molecule types in the Primary Immune Deficiency pipeline products market are gene-modified cell therapy, antibody, small molecule, cell therapy, biologic, gene therapy, monoclonal antibody, recombinant enzyme, and recombinant protein.
-
Which are the major companies in the Primary Immune Deficiency pipeline products market?
Some of the major companies in the Primary Immune Deficiency pipeline products market are Takeda Pharmaceutical Co Ltd, X4 Pharmaceuticals Inc, ADMA Biologics Inc, Cellectis SA, Grifols SA, Mustang Bio Inc, Biotest AG, Cellective BioTherapy Inc, Chengdu Rongsheng Pharmaceutical Co Ltd, and Clinigen Group Plc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports